By: Sanjeev Giri, Udaipur Rajasthan, Nirbhay Kumar Tiwari, Ramesh Patnam, Bengaluru Karnataka, Avinash Kumar, Rameshwar Ameta
Dasatinib (DAS) is a tyrosine kinase inhibitor used in the treatment of chronic myeloid leukemia (CML) and erythromycin (ERY) is macrolide antibiotic used to treat a range of inflammatory conditions are often co-administered in clinical practice. The simultaneous estimation of DAS and ERY helps in understanding the pharmacokinetics and drug–drug interactions. In this respect, we presented novel, sensitive, and validated bio-analytical LC-ESI-MS/MS method for simultaneous estimation of DAS and ERY in CD-1 mice plasma. The LLOQ was 2.0 ng/mL with an S/N ratio of 15. This validated method was used to study the PK of DAS and ERY in mice following intravenous and oral administration. The DAS was administered at 5 mg/kg via both oral and intraveneous route, whereas ERY was administered at 50 mg/kg orally and 5 mg/kg intraveneousaly. Following intravenous dosing, DAS showed high clearance and distribution, while ERY exhibited high clearance and distribution. The oral bioavailability was 64% for DAS and 21% for ERY. When co-administered orally at 5 mg/kg for DAS and 50 mg/kg of ERY, the












